CMPX Stock News & Catalysts – Compass Therapeutics

FEATURED

Compass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate Update

New

Compass is advancing preparations for a BLA submission for tovecimig in patients with BTC and plans to further engage with the FDA.Data from the COMPANION-002 study of tovecimig, including newly disclosed durability of

Summary

Nov 9, 2026, 8:00 AM ·Globe Newswire

RECENT

Compass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual Meeting

CTX-10726, a PD-1 x VEGF-A bispecific antibody discovered and engineered at Compass, exhibits a unique mechanism of action that has not been previously reported in this class of drugs, characterized by VEGF-A-dependent

Nov 6, 2026, 9:00 AM ·Globe Newswire

Compass Therapeutics to Participate in Upcoming November Investor Events

BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple

Nov 2, 2026, 9:00 AM ·Globe Newswire

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

As published in the Journal of Clinical Oncology (JCO) and presented at ESMO, COMPANION-002 met its primary endpoint of ORR and key secondary endpoint of PFS, with a 56% reduction in the risk of disease progression or

Oct 24, 2026, 4:15 AM ·Globe Newswire

Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple

Oct 14, 2026, 4:30 PM ·Globe Newswire

Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback

The FDA recommended that Compass conduct a trial to demonstrate a survival benefit prior to submitting a BLA for tovecimig.Compass does not believe that a new trial is warranted prior to submitting a BLA based on the

Sep 22, 2026, 8:30 AM ·Globe Newswire

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

The Company expects feedback from the FDA this quarter regarding the COMPANION-002 Phase 2/3 data for tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), prior to a potential BLA

Aug 6, 2026, 7:30 AM ·Globe Newswire

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple

Jul 17, 2026, 10:42 AM ·Globe Newswire

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs

Issued on behalf of GT Biopharma, Inc.GT Biopharma, Inc. (NASDAQ:GTBP) says newly implemented AI-based tools are accelerating its drug discovery and engineering, with multiple new development candidates expected to move

Jun 30, 2026, 9:00 AM ·PRNewswire

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Issued on behalf of GT Biopharma, Inc. Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for

Jun 12, 2026, 8:10 AM ·Globe Newswire

Compass Therapeutics to Participate in Upcoming June Investor Events

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human

May 28, 2026, 7:30 AM ·Globe Newswire

Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting

CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with advanced malignancies

May 21, 2026, 5:00 PM ·Globe Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ:CMPX). Such investors are advised to contact

May 19, 2026, 6:09 PM ·Globe Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ:CMPX). Such investors are advised to

May 14, 2026, 11:01 PM ·PRNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ:CMPX). Such investors are advised to contact

May 12, 2026, 4:45 PM ·Globe Newswire

Compass Therapeutics, Inc. CMPX · News